Asiv.Si
ASIV.SI operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
Business. ASIV.SI operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ASIV.SI operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
ASIV.SI exhibits a strong liquidity position, with a current ratio of 13.32, indicating that the company holds significantly more current assets than current liabilities. The company's cash and equivalents amount to SGD 7,859,930, which is a substantial portion of its total assets of SGD 10,108,660. However, the company's free cash flow is negative at SGD -6,091,760, suggesting that capital expenditures and operational cash outflows are outpacing inflows.
Profitability metrics for ASIV.SI are negative, with a return on equity of -68.81% and a return on assets of -64%. These figures are well below the typical performance of the healthcare services and equipment industry, which generally sees positive returns on equity and assets. The company's operating income is also negative at SGD -6,453,570, indicating that operational costs are exceeding revenues.
ASIV.SI's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. The company's geographic exposure is not disclosed in the available data, but the revenue is reported in SGD, suggesting a primary market in Singapore. There is no indication of significant international operations or revenue diversification.
The company's growth trajectory is uncertain, as the available data does not provide forward-looking revenue projections or outlooks. Historical revenue for the latest period is SGD 2,320,410, but the company's net income is negative at SGD -6,469,350. This suggests that the company is not currently generating profits and may be in a restructuring or investment phase.
Risk factors for ASIV.SI include the company's negative net income and operating income, which could affect its ability to sustain operations without external financing. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the company's negative free cash flow and operating cash flow of SGD 83,000 suggest that it may need to secure additional financing in the near term.
Recent events for ASIV.SI are not detailed in the available data. The company's latest financial snapshot is from the market data source, but no specific filings or transcripts are cited. The absence of recent events or disclosures may indicate a lack of material developments in the company's operations or financial status.
- ASIV.SI has a strong liquidity position with a current ratio of 13.32 and significant cash reserves.
- The company is currently unprofitable, with a return on equity of -68.81% and a return on assets of -64%.
- Revenue is concentrated in a single segment, and geographic exposure is not disclosed.
- The company's growth trajectory is unclear, with no forward-looking revenue projections provided.
- Risk factors include negative net income and operating income, but liquidity and dilution risks are currently low.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ASIV.SI Market data — financials · 2026-05-27